Rhoda Wilson

In 2015 the US Food and Drug Administration (“FDA”) issued guidance on how to conduct shedding studies during the preclinical and clinical development of virus or bacteria-based gene therapy products. Shedding, as described by the FDA, is the excretion or release of a product from a vaccinated person’s body. The shed gene therapy product may be infectious and so raises safety concerns “related to the risk of transmission to untreated individuals.”

Various studies and documents, including a study by Pfizer, indicate vaccine shedding and transmission are occurring.

A University of Colorado study published in May provided evidence “for a new mechanism by which herd immunity may be manifested – the aerosol transfer of antibodies between immune and non-immune hosts.”

… Additionally, in February 2022, Dr. Philippe van Welbergen demonstrated that “shards” of graphene are being transmitted from vaccinated to unvaccinated people.